Neupro

GPTKB entity

Statements (55)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:class dopamine agonist
gptkbp:clinical_trial Phase III trials
gptkbp:clinical_use symptomatic treatment
improving quality of life
long-term management
gptkbp:contraindication severe liver impairment
concurrent use of certain medications
hypersensitivity to rotigotine
gptkbp:dosage_form gptkb:patches
gptkbp:drug_interactions antidepressants
antipsychotics
antiemetics
other dopamine agonists
gptkbp:effective_date gptkb:2007
gptkbp:financial_support avoid alcohol
do not stop abruptly
monitor for unusual urges
report any skin reactions
gptkbp:form gptkb:patches
https://www.w3.org/2000/01/rdf-schema#label Neupro
gptkbp:ingredients rotigotine
gptkbp:manufacturer gptkb:UCB_S._A.
gptkbp:marketed_as gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
gptkbp:mechanism_of_action stimulates dopamine receptors
gptkbp:packaging single-use patches
gptkbp:requires prescription only
gptkbp:research_focus Parkinson's disease treatment
restless legs syndrome treatment
dopamine receptor activity
gptkbp:route_of_administration transdermal
gptkbp:side_effect dizziness
headache
nausea
vomiting
insomnia
skin reactions
somnolence
gptkbp:storage room temperature
protected from light
gptkbp:strength 10 mg/24 hours
2 mg/24 hours
4 mg/24 hours
6 mg/24 hours
8 mg/24 hours
12 mg/24 hours
16 mg/24 hours
24 mg/24 hours
gptkbp:used_for gptkb:neurodegenerative_diseases
gptkb:restless_legs_syndrome
gptkbp:bfsParent gptkb:UCB_S._A.
gptkbp:bfsLayer 6